Adamas Pharmaceuticals, Inc. announced that on December 7, 2015, Jeffrey Knapp, Chief Operating Officer, resigned effective January 29, 2016, for personal reasons. John MacPhee, a member of board of directors, will provide commercial advisory oversight on an interim basis until a Chief Commercial Officer is named.
Adamas Pharmaceuticals, Inc.
Equities
ADMS
US00548A1060
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+43.36% | 58.06B | |
-5.31% | 40.53B | |
+37.52% | 38.99B | |
+14.75% | 26.7B | |
-12.56% | 26.56B | |
-22.45% | 18.98B | |
+0.04% | 12.17B | |
+25.12% | 12B | |
+26.04% | 11.92B |